Novo Nordisk AS (WBO:NNO2) 1-Year Sharpe Ratio: -0.30 (As of Jul. 08, 2026)


WBO:NNO2 Novo Nordisk AS WBO:NNO2
71 GF Score
Price €43.59
GF Value €120.11
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS 1-Year Sharpe Ratio?

Novo Nordisk AS WBO:NNO2 +1.76% 71 1-Year Sharpe Ratio is -0.30 as of Jul. 08, 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.11 (Significantly Undervalued). The stock has 4 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-08), Novo Nordisk AS's 1-Year Sharpe Ratio is -0.30.

Novo Nordisk AS  (WBO:NNO2) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Novo Nordisk AS 1-Year Sharpe Ratio Related Terms

WBO:NNO2 vs LLY, JNJ, ABBV: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's 1-Year Sharpe Ratio falls into.


WBO:NNO2
71GF Score
Novo Nordisk AS WBO:NNO2
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.30 mean?
Novo Nordisk AS (WBO:NNO2) has a 1-Year Sharpe Ratio of -0.30 as of Jul. 08, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's 1-Year Sharpe Ratio too high?
Novo Nordisk AS's current 1-Year Sharpe Ratio is -0.30. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's 1-Year Sharpe Ratio compare to LLY and JNJ?
Novo Nordisk AS's 1-Year Sharpe Ratio of -0.30 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Novo Nordisk AS and its competitors. Novo Nordisk AS's current 1-Year Sharpe Ratio is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.11, compared to a current price of €43.59 — trading 63.7% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.30. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current 1-Year Sharpe Ratio is -0.30 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.59 is trading 63.7% below its estimated GF Value™ of €120.11. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • 1-Year Sharpe Ratio: -0.30
  • GF Value™: €120.11 vs. price of €43.59 (63.7% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score

Get the complete analysis for WBO:NNO2

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.59
Price
€120.11
GF Value